Is Positive Camzyos Adolescent Trial Data Altering The Investment Case For Bristol-Myers Squibb (BMY)?

• In late March 2026, Bristol Myers Squibb reported that its Phase 3 SCOUT-HCM trial of Camzyos in adolescents with symptomatic obstructive hypertrophic cardiomyopathy met its primary endpoint, delivering a clinically meaningful and statistically significant reduction in Valsalva LVOT gradient and supportive safety data versus placebo over 28 weeks.
• The findings, showcased at the American College of Cardiology 2026 meeting and published in The New England Journal of Medicine, highlight Camzyos’ potential to extend into younger patients and broaden Bristol Myers Squibb’s cardiology franchise beyond its current adult oHCM indication.
• We’ll examine how Camzyos’ positive adolescent SCOUT-HCM results could reinforce Bristol Myers Squibb’s pipeline-led growth narrative and risk balance.

Find 59 companies with promising cash flow potential yet trading below their fair value.

Bristol-Myers Squibb Investment Narrative Recap

To stay invested in Bristol Myers Squibb today, you need to believe that its newer drugs and partnerships can gradually offset pressure from looming patent losses and pricing reforms, while the balance sheet and dividend remain manageable despite high debt. The Camzyos adolescent SCOUT-HCM win supports the idea of a broader cardiology platform, but it does not change the near term focus on earnings pressure from guidance cuts and patent cliff concerns.

Among recent news, the expanded collaboration with Janux Therapeutics stands out next to the Camzyos update. By advancing a tumor activated therapeutic candidate and triggering a US$35,000,000 milestone payment, Bristol Myers Squibb is reinforcing its oncology pipeline and external innovation approach, which many investors watch as a possible counterweight to future Eliquis and Opdivo revenue erosion.

Yet, against these encouraging trial results, investors should also be aware that...

Read the full narrative on Bristol-Myers Squibb (it's free!)

Bristol-Myers Squibb's narrative projects $41.3 billion revenue and $9.2 billion earnings by 2028. This assumes revenues decline by 4.7% per year and earnings rise by about $4.2 billion from $5.0 billion today.

Uncover how Bristol-Myers Squibb's forecasts yield a $59.91 fair value, in line with its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were already assuming revenue could fall about 8 percent a year to roughly US$37,500,000,000 by 2029, so if you think partnerships and late stage data will meaningfully offset that, your view is already less pessimistic than theirs.

Explore 11 other fair value estimates on Bristol-Myers Squibb - why the stock might be worth over 2x more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Bristol-Myers Squibb research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Bristol-Myers Squibb research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Bristol-Myers Squibb's overall financial health at a glance.

Searching For A Fresh Perspective?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Capitalize on the AI infrastructure supercycle with our selection of the 36 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 26 best rare earth metal stocks of the very few that mine this essential strategic resource.
• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com